Dean Tuck – Managing Director – Dreadnought Resources (ASX:DRE) is a highly active West Australian mineral explorer focused on finding the metals needed now and in the future.
Copyright 2024 – Finance News Network
Source: Finance News Network
05 Apr 2023 - North Stawell Minerals Limited (ASX:NSM) CEO Russell Krause provides an update, discussing the company's progress to date, the most prospective targets, and milestones ahead.
Read More21 May 2021 - Hazer Group Limited (ASX:HZR) CEO & Managing Director Geoff Ward provides an update on the company's Commercial Development Project at the Woodman Point Wastewater Treatment Plant south of Perth, a 100 tonne per annum hydrogen production facility using waste gas produced through the water treatment facilities.
Read More30 Mar 2022 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the company's LAG-3-related therapies, outlining future plans and expected data readouts for Immutep's lead drug, eftilagimod alpha.
Read More27 Sep 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes discusses the appointment of a US distributor for the company's APAS Independence instrument.
Read More30 Jul 2021 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, provides an update on activities from the company's June quarter, discussing growth in platforms and infrastructure and the recent capital raise.
Read More26 May 2020 - LBT Innovations Limited (ASX:LBT) Managing Director and CEO Brent Barnes talks about progress with the company's microbiology culture plate reading device APAS Independence, which uses artificial intelligence to read and interpret plates, additional analysis module development, sales pipeline and strategy.
Read More05 Dec 2019 - Memphasys Limited (ASX:MEM) Executive Chairman, Alison Coutts talks about progress with the company's human assisted reproductive device for the separation of sperm cells in IVF clinics.
Read More25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
Read More25 Nov 2019 - Lepidico (ASX:LPD) Managing Director, Joe Walsh provides an update on drill results from its recently acquired Rubicon and Helikon deposits in Namibia, L-Max Pilot Plant trial results and outlook.
Read More27 Jan 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt analyses December's breast cancer data, and provides an update on efti's position and outlook.e sites.
Read More
